VH4524184 clinical trials
Also written VH4524184.
How each study uses VH4524184 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VH4524184 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VH4524184
- 6
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Midazolam (1) · Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test VH4524184.
- Jun 2027A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Phase 2 · ViiV Healthcare
Studies
Open first, then newest update. How each study uses VH4524184 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- First Time in Human Study of Long Acting VH4524184 FormulationsRecruitingPhase 1ViiV HealthcareNCT06310551Written as VH4524184 Formulation A SC
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)RecruitingPhase 2ViiV HealthcareNCT07202546Written as VH4524184
- Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184RecruitingPhase 1ViiV HealthcareNCT07636928Written as VH4524184
- A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy AdultsCompletedPhase 1ViiV HealthcareNCT07066722Written as VH4524184
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) ActivityCompletedPhase 1ViiV HealthcareNCT05631704Written as VH4524184
- VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1CompletedPhase 2ViiV HealthcareNCT06214052Written as VH4524184
- A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female ParticipantsCompletedPhase 1ViiV HealthcareNCT06310616Written as VH4524184